Healing the Fundamental Unit of Heredity (Gene Therapy): Current Perspective and What the Future Holds

Bunga Anggreini Sari, Azalia Talitha Zahra, Ganda Purba Tasti, Ziske Maritska


The ability to make precise adjustments to the human genome has been a goal of healing in which gene also introduces as the fundamental unit of heredity, in biomolecular technology in genetic diseases have opened new knowledge such as gene therapy. Gene therapy is a technique to repair DNA where its usage is to treat the malignancy and inherited genetic diseases. Gene therapy is a choice to the genetic cloth that goals to remedy a sickness this is hard to deal with or perhaps has no treatment. Currently, gene remedy is done in approaches to patients, specifically embryonic cells and somatic cells, every in vivo and ex vivo. Moral considerations with modification of the difficulty's cells and oversight of regulation and reagents want to be taken into consideration within the gene therapy project. Applications for using gene remedies have begun to be widely used, which include in case of maximum cancers, coronary heart disorder, infectious sicknesses, and others. Gene therapy has spread to a wide range of applications then go beyond the modification of genetic disorders. Advances in genetic modification of cancer cells and immunity and the use of viruses and bacteria to control cancer cells have resulted in many clinical trials and product developments for cancer treatment. The miracles and blessings of gene therapy are might believe, but even though they are being studied and developed now and, in the future, so that the desire for gene therapy may be even better future.

Keywords: gene therapy, genetic recombination, gene therapy application

Full Text:



Gonçalves GAR, Paiva RMA. Gene therapy: advances, challenges and perspectives. Einstein (Sao Paulo). 2017; 15(3): 369-75, CrossRef.

Jackson M, Marks L, May GHW, Wilson JB. The genetic basis of disease. Essays Biochem. 2018; 62(5): 643-723, CrossRef.

Kumar SR, Markusic DM, Biswas M, High KA, Herzog RW. Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev. 2016; 3: 16034, CrossRef.

Hampson G, Towse A, Pearson SD, Dreitlein WB, Henshall C. Gene therapy: evidence, value and affordability in the US health care system. J Comp Eff Res. 2018; 7(1): 15-28, CrossRef.

Smith CIE, Blomberg P. Genterapi – från idé till verklighet - Ännu har få patienter behandlats och preparaten är ofta mycket dyra – men utvecklingen går fort nu [Gene therapy – from idea to reality]. Lakartidningen. 2017; 114: EWYL, article.

Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil JA, Hongeng S, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2018; 378(16): 1479-93, CrossRef.

George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017; 377: 2215-27, CrossRef.

Carpenter TO, Whyte MP, Imel EA, Boot AM, Högler W, Linglart A, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018; 378: 1987-98, CrossRef.

Collins FS, Gottlieb S. The next phase of human gene-therapy oversight. N Engl J Med. 2018; 379: 1393-5, CrossRef.

Ginn S, Alexander I. 2016. Gene therapy. In: Balakrishnan N, Colton T, Everitt B, Piegorsch W, Ruggeri F, Teugels JL, editor. Wiley StatsRef: Statistics Reference Online. New Jersey: John Wiley & Sons; 2016. p.1-19, CrossRef.

Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: An update. J Gene Med. 2018; 20: e3015, CrossRef.

Glorioso JC, Lemoine N. Gene therapy-from small beginnings to where we are now. Gene Ther. 2017; 24(9): 495-6, CrossRef.

Macpherson I, Roqué MV, Segarra I. Ethical challenges of germline genetic enhancement. Front Genet. 2019; 10: 767, CrossRef.

Patil S, Al-Zoubi IA, Raghuram PH, Misra N, Yadav N, Alam MK. Gene therapy: A comprehensive review. Int Med J. 2018; 25(6): 361-4, article.

Wolf DP, Mitalipov PA, Mitalipov SM. Principles of and strategies for germline gene therapy. Nat Med. 2019; 25(6): 890-7, CrossRef.

Spatz MA. Genetics home reference. J Med Libr Assoc. 2004; 92(2): 282-3, article.

Sinha S, Ghosh A, Rao JG, Jotwani G, Kharkwal G, editors. National Guidelines for Gene TherapyProduct Development and Clinical Trials. New Delhi: Indian Council of Medical Research; 2019, article.

Yazdani A, Alirezaie Z, Motamedi M, Amani J. Gene therapy: a new approach in modern medicine. Int J Med Rev. 2018; 5(3): 36-17. Yazdani A, Alirezaie Z, Motamedi M, Amani J. Gene therapy: a new approach in modern medicine. Int J Med Rev. 2018; 5(3): 36-17, article.

Silvia Hardiany N. Metode transfer asam nukleat sebagai dasar terapi gen. eJKI. 2017; 4(3): 204-10, article.

Santiago-Ortiz JL, Schaffer DV. Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Release. 2016; 240: 287-301, CrossRef.

Gabisonia K, Recchia FA. Gene therapy for heart failure: new perspectives. Curr Heart Fail Rep. 2018; 15(6): 340-9, CrossRef.

Demirci S, Uchida N, Tisdale JF. Gene therapy for sickle cell disease: An update. Cytotherapy. 2018; 20(7): 899-910, CrossRef.

Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019; 70: 273-288, CrossRef.

Carlton Gyles. The promise of gene therapy. Can Vet J. 2018; 59(6): 571-4, article.

Salzman R, Cook F, Hunt T, Malech HL, Reilly P, Foss-Campbell B, et al. Addressing the value of gene therapy and enhancing patient access to transformative treatments. Mol Ther. 2018; 26(12): 2717-26, CrossRef.

Keeler AM, ElMallah MK, Flotte TR. Gene therapy 2017: progress and future directions. Clin Transl Sci. 2017; 10(4): 242-8, CrossRef.

DOI: https://doi.org/10.21705/mcbs.v5i2.202

Indexed by:




Cell and BioPharmaceutical Institute